Chronic pain cannot be eliminated. It is a lifelong pain. It is a pain that not only limits the patients but also affects their close circles: family, friends, work colleagues…
Chronic pain is the medical indication for which the largest number of medical cannabis licenses are issued. The most updated data (February 2023) show that of 123,714 licensees, 53% (66,352) are suffering from chronic neuropathic pain1.
Uri Shultz, Suffers from Chronic Neuropathic Pain due to Multiple Lumbar Herniated Discs,
Treated with SyqeAir Inhaler since 2017
How to Obtain a Medical Cannabis License for Chronic Neuropathic Pain?
According to Protocol 106 of the Ministry of Health, to meet the conditions for obtaining a license for medical cannabis treatment to reduce the intensity of chronic neuropathic pain, the following conditions must be met:
- The patient should be in continuous treatment for at least a year with a doctor who specializes in pain management
- It must be proven (by presenting a drug purchase report) that the conventional treatment has been fully exhausted2
Chronic lower back pain (which lasts six months or more, despite pain relief treatment) and chronic pain due to herniated discs are two of the most common medical problems. The pains arise from various reasons and can be observed in different intensities from person to person. About 40% of the population suffers or will suffer from back pain during their lifetime; the risk increases among women between the ages of 40 and 80. Over the years, the proportion of patients who suffer from these kinds of pain and turn to the possibility of reducing the pain intensity with medical cannabis increases. This is mainly because conventional medicines failed to alleviate their pain or caused side effects that did not allow them to continue leading a daily routine. For these exact reasons, an advanced technological solution was developed: the SyqeAir Inhaler and Medical Cannabis Cartridge.
SyqeAir Inhaler and Medical Cannabis Cartridge: Pain Relief Starting Within 5 Minutes
The SyqeAir Inhaler provides patients with a reduction in pain whose onset can be felt 5 minutes after the inhalation3. Adjustment of a personal optimal dosage by a qualified nurse reduces to a minimum (or to a zero) the adverse effects4 compared to the other approved routes of administration5 (smoking, vaporization, and oil) and makes it possible to establish a stable daily routine alongside the chronic pain.
What is the SyqeAir inhaler? Learn more on our Q&A Page>>
Chronic Neuropathic Pain and Medical Cannabis
A statistical analysis that compared categories in various meta-analysis studies (i.e., articles that collect data from all clinical studies and summarize their results, statistically speaking) concluded that the effectiveness of treating chronic neuropathic pain using cannabinoids is not higher than the effectiveness of treating chronic non-neuropathic pain (muscle pain, bone pain, or pain of another origin)6. This means that although the regulation in Israel states that cannabis is only suitable for treating chronic neuropathic pain, it does not prevent it from being able to help with pain of a different origin as well.
92% of SyqeAir patients attested to an improvement in quality of life4.
What else have we discovered about our patients? Learn more on our Clinical Trials Page>>
- Current data from patient licenses of the Israeli Medical Cannabis Unit (HaYakar), February 2023
- Protocol 106 of the Israeli Medical Cannabis Unit (HaYakar)
- Almog S, et al. European Journal of Pain, 24(8), 1505-1516.
- Aviram J, et al. (2022) PAIN Reports. 7(3). e1011. Among the participants in the study.
- Aviram, J. (2021). European Journal of Pain, 25(2), 359-374.
- Wong, S, et al. (2020) J. Neuroimmune Pharmacol. 15, 821-829.
SyqeAir Inhaler
Pain reduction with minimum psychoactive adverse effects, for optimal quality of life
For more information, contact us:
